What is Hcw Biologics Inc.'s earnings per share (EPS)?

Hcw Biologics Inc. (HCWB) reported diluted earnings per share of $-10.63 for fiscal year 2025. This represents a 65.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Hcw Biologics Inc. Financials

HCWB

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE December

This page shows Hcw Biologics Inc. (HCWB) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI HCWB FY2025 2026-05-14

HCW Biologics still behaves like a funded R&D enterprise, with operating cash burn far outweighing current product revenue.

FY2025's narrower net loss did not come from a healthier sales engine: revenue fell from $2.6M in FY2024 to $54K. Yet operating cash burn was still -$13.4M, which says the accounting improvement came from cost or non-operating changes rather than from a self-supporting commercial base.

Capex is not the problem: free cash flow matched operating cash flow in FY2025 because capital spending was $0. That means the cash drain comes from running the organization and funding research, not from maintaining a capital-heavy asset base.

Liquidity is the tight constraint, not long-term borrowing: cash was $2.0M and the current ratio was 0.1x at FY2025 year-end. Near-term obligations still dominate the balance sheet, with current liabilities of $21.1M against current assets of $2.3M.

Financial Health Signals

Financial Profile 17/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Hcw Biologics Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Hcw Biologics Inc. has an operating margin of -24270.7%, meaning the company retains $-24271 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -1147.6% the prior year.

Growth

Hcw Biologics Inc.'s revenue declined 97.9% year-over-year, from $2.6M to $54K. This contraction results in a growth score of 0/100.

Leverage

100

Hcw Biologics Inc. carries a low D/E ratio of 0.00, meaning only $0.00 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Hcw Biologics Inc.'s current ratio of 0.11 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Cash Flow

While Hcw Biologics Inc. generated -$13.4M in operating cash flow, capex of $0 consumed most of it, leaving -$13.4M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.

Returns

Hcw Biologics Inc. generates a -287.9% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100.

Piotroski F-Score Weak

2/9

Hcw Biologics Inc. passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Low Quality

1.68x

For every $1 of reported earnings, Hcw Biologics Inc. generates $1.68 in operating cash flow (-$13.4M OCF vs -$8.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-15.6x

Hcw Biologics Inc. earns $-15.6 in operating income for every $1 of interest expense (-$13.2M vs $845K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$54K

YoY-97.9%

5Y CAGR-57.9%

Hcw Biologics Inc. generated $54K in revenue in fiscal year 2025. This represents a decrease of 97.9% from the prior year.

EBITDA

-$12.1M

YoY+57.1%

Hcw Biologics Inc.'s EBITDA was -$12.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 57.1% from the prior year.

Net Income

-$8.0M

YoY+73.5%

Hcw Biologics Inc. reported -$8.0M in net income in fiscal year 2025. This represents an increase of 73.5% from the prior year.

EPS (Diluted)

$-10.63

YoY+65.7%

Hcw Biologics Inc. earned $-10.63 per diluted share (EPS) in fiscal year 2025. This represents an increase of 65.7% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$13.4M

YoY+7.6%

Hcw Biologics Inc. generated -$13.4M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 7.6% from the prior year.

Cash & Debt

$2.0M

YoY-58.2%

5Y CAGR-25.4%

Hcw Biologics Inc. held $2.0M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

N/A

Margins & Returns

Gross Margin

20.0%

YoY-17.4pp

Hcw Biologics Inc.'s gross margin was 20.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 17.4 percentage points from the prior year.

Operating Margin

-24270.7%

YoY-23123.1pp

5Y CAGR-24128.7pp

Hcw Biologics Inc.'s operating margin was -24270.7% in fiscal year 2025, reflecting core business profitability. This is down 23123.1 percentage points from the prior year.

Net Margin

-14677.1%

YoY-13507.4pp

5Y CAGR-14535.6pp

Hcw Biologics Inc.'s net profit margin was -14677.1% in fiscal year 2025, showing the share of revenue converted to profit. This is down 13507.4 percentage points from the prior year.

Return on Equity

-287.9%

Hcw Biologics Inc.'s ROE was -287.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.

Capital Allocation

R&D Spending

$5.4M

YoY-14.8%

5Y CAGR-5.6%

Hcw Biologics Inc. invested $5.4M in research and development in fiscal year 2025. This represents a decrease of 14.8% from the prior year.

Share Buybacks

N/A

Capital Expenditures

YoY-100.0%

Hcw Biologics Inc. invested $0 in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 100.0% from the prior year.

HCWB Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$54K-97.9%	$2.6M-9.7%	$2.8M-57.7%	$6.7M	$0-100.0%	$4.1M
Cost of Revenue	$43K-97.3%	$1.6M-29.5%	$2.3M-44.8%	$4.1M	$0	N/A
Gross Profit	$11K-98.9%	$959K+71.2%	$560K-78.3%	$2.6M	$0	N/A
R&D Expenses	$5.4M-14.8%	$6.4M-16.8%	$7.7M-17.8%	$9.3M+14.2%	$8.2M+12.7%	$7.3M
SG&A Expenses	$7.7M+13.0%	$6.8M+0.5%	$6.8M-18.6%	$8.3M+60.3%	$5.2M+94.6%	$2.7M
Operating Income	-$13.2M+55.3%	-$29.5M-14.5%	-$25.7M-70.6%	-$15.1M-12.8%	-$13.4M-129.5%	-$5.8M
Interest Expense	$845K+29.2%	$654K+131.2%	$283K+123.5%	$127K	$0	N/A
Income Tax	$0	$0	$0	$0	$0	$0
Net Income	-$8.0M+73.5%	-$30.0M-20.1%	-$25.0M-67.7%	-$14.9M-15.8%	-$12.9M-121.7%	-$5.8M
EPS (Diluted)	$-10.63+65.7%	$-30.96-4322.9%	$-0.70-66.7%	$-0.42+39.1%	$-0.69	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$6.5M+24123.5%	$27K+73.1%	$16K+138.3%	$7K+29.3%	$5K-98.7%	$395K-7.4%	$426K-31.1%	$619K
Cost of Revenue	$11K-48.8%	$22K+73.1%	$12K+138.3%	$5K+29.3%	$4K-98.7%	$316K-7.4%	$341K-22.2%	$438K
Gross Profit	$6.5M+120816.9%	$5K+73.1%	$3K+138.2%	$1K+29.3%	$1K-98.7%	$79K-7.4%	$85K-52.7%	$180K
R&D Expenses	$1.3M-5.6%	$1.3M-5.1%	$1.4M+14.5%	$1.2M-17.0%	$1.5M+40.9%	$1.0M-11.6%	$1.2M-41.5%	$2.0M
SG&A Expenses	$1.8M+22.8%	$1.5M-20.8%	$1.9M-10.1%	$2.1M-5.9%	$2.2M+10.1%	$2.0M+23.8%	$1.6M+2.5%	$1.6M
Operating Income	$3.2M+172.9%	-$4.4M-34.9%	-$3.3M+5.0%	-$3.5M-76.2%	-$2.0M+37.4%	-$3.1M+14.7%	-$3.7M+75.7%	-$15.1M
Interest Expense	$109K-53.2%	$233K+83.7%	$127K-44.4%	$229K-10.6%	$256K-3.7%	$266K+15.9%	$229K+43.5%	$160K
Income Tax	$330K	N/A	N/A	N/A	$0	N/A	N/A	N/A
Net Income	$3.5M+382.8%	$719K+115.8%	-$4.6M-136.3%	-$1.9M+12.3%	-$2.2M+34.9%	-$3.4M+13.6%	-$3.9M+74.5%	-$15.3M
EPS (Diluted)	$0.37	N/A	$-2.02+70.3%	$-6.79	$-1.97	N/A	$-4.13+74.4%	$-16.16

HCWB Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$24.5M-18.9%	$30.2M+6.0%	$28.5M-39.1%	$46.8M-12.5%	$53.5M+247.5%	$15.4M
Current Assets	$2.3M-59.9%	$5.7M-11.0%	$6.4M-81.2%	$34.1M-15.8%	$40.5M+233.2%	$12.1M
Cash & Equivalents	$2.0M-58.2%	$4.7M+30.0%	$3.6M-83.9%	$22.3M+90.3%	$11.7M+38.7%	$8.5M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$21.8M-41.2%	$37.0M+145.9%	$15.1M+60.5%	$9.4M+304.1%	$2.3M-92.8%	$32.1M
Current Liabilities	$21.1M-28.9%	$29.6M+238.7%	$8.7M+195.9%	$3.0M+27.3%	$2.3M+131.9%	$1.0M
Long-Term Debt	$0-100.0%	$7.4M+17.0%	$6.3M-1.6%	$6.4M	$0	N/A
Total Equity	$2.8M+140.8%	-$6.8M-150.3%	$13.5M-64.0%	$37.4M-26.9%	$51.2M+406.2%	-$16.7M
Retained Earnings	-$108.5M-7.9%	-$100.6M-42.6%	-$70.5M-54.9%	-$45.5M-48.6%	-$30.6M-83.3%	-$16.7M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$27.3M+11.5%	$24.5M-3.6%	$25.4M-12.0%	$28.9M+10.0%	$26.3M-13.1%	$30.2M+13.9%	$26.6M-1.0%	$26.8M
Current Assets	$1.7M-24.6%	$2.3M+43.8%	$1.6M-45.2%	$2.9M+52.9%	$1.9M-66.8%	$5.7M+172.1%	$2.1M-12.2%	$2.4M
Cash & Equivalents	$1.2M-37.1%	$2.0M+78.0%	$1.1M-55.0%	$2.4M+120.2%	$1.1M-76.3%	$4.7M+368.3%	$998K-14.0%	$1.2M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$21.6M-0.8%	$21.8M-21.0%	$27.6M-4.9%	$29.0M-16.9%	$34.8M-5.8%	$37.0M+1.3%	$36.5M+10.3%	$33.1M
Current Liabilities	$20.0M-5.2%	$21.1M-21.6%	$26.9M+0.1%	$26.8M-1.1%	$27.1M-8.4%	$29.6M-1.4%	$30.1M+29.5%	$23.2M
Long-Term Debt	N/A	$0	$0-100.0%	$367K-95.2%	$7.7M+4.4%	$7.4M+14.2%	$6.5M-34.7%	$9.9M
Total Equity	$5.8M+108.4%	$2.8M+231.2%	-$2.1M-3954.5%	-$52K+99.4%	-$8.6M-26.5%	-$6.8M+32.1%	-$10.0M-58.3%	-$6.3M
Retained Earnings	-$105.0M+3.2%	-$108.5M+0.7%	-$109.2M-4.4%	-$104.7M-1.9%	-$102.8M-2.2%	-$100.6M-3.5%	-$97.2M-4.2%	-$93.3M

HCWB Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$13.4M+5.9%	-$14.2M+36.8%	-$22.5M-116.8%	-$10.4M+5.4%	-$11.0M-5.2%	-$10.4M
Capital Expenditures	$0-100.0%	$262K-95.8%	$6.2M-39.6%	$10.3M+21640.3%	$47K-74.7%	$187K
Free Cash Flow	-$13.4M+7.6%	-$14.5M+49.5%	-$28.7M-39.0%	-$20.7M-87.4%	-$11.0M-3.8%	-$10.6M
Investing Cash Flow	$0+100.0%	-$262K-106.9%	$3.8M-74.2%	$14.7M+142.0%	-$35.0M-18658.6%	-$187K
Financing Cash Flow	$10.7M-31.5%	$15.6M+107217.9%	-$15K-100.2%	$6.3M-87.3%	$49.3M+320.5%	$11.7M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$1.6M+53.1%	-$3.4M-3.6%	-$3.2M+1.3%	-$3.3M+6.6%	-$3.5M-24.0%	-$2.8M+3.1%	-$2.9M+39.8%	-$4.9M
Capital Expenditures	N/A	$0	$0	$0	$0-100.0%	$113K+206.0%	$37K+299.6%	-$19K
Free Cash Flow	N/A	-$3.4M-3.6%	-$3.2M+1.3%	-$3.3M+6.6%	-$3.5M-19.2%	-$2.9M+0.5%	-$3.0M+39.3%	-$4.9M
Investing Cash Flow	N/A	$0	$0	$0	$0+100.0%	-$113K-206.0%	-$37K-299.6%	$19K
Financing Cash Flow	$852K-79.8%	$4.2M+121.9%	$1.9M-58.9%	$4.6M+8788.1%	-$53K-100.8%	$6.6M+136.6%	$2.8M+45.8%	$1.9M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

HCWB Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	20.0%-17.4pp	37.4%+17.7pp	19.7%-18.8pp	38.5%	N/A	N/A
Operating Margin	-24270.7%-23123.1pp	-1147.6%-242.6pp	-905.0%-680.6pp	-224.3%	N/A	-142.1%
Net Margin	-14677.1%-13507.4pp	-1169.7%-290.2pp	-879.5%-657.9pp	-221.7%	N/A	-141.5%
Return on Equity	-287.9%	N/A	-185.7%-145.9pp	-39.8%-14.7pp	-25.1%	N/A
Return on Assets	-32.5%+66.8pp	-99.3%-11.6pp	-87.7%-55.8pp	-31.8%-7.8pp	-24.0%+13.6pp	-37.7%
Current Ratio	0.11-0.1	0.19-0.5	0.73-10.8	11.52-5.9	17.44+5.3	12.14
Debt-to-Equity	0.00+1.1	-1.09-1.6	0.47+0.3	0.17+0.2	0.00+1.9	-1.92
FCF Margin	-24693.2%-24128.7pp	-564.5%+446.0pp	-1010.5%-703.1pp	-307.4%	N/A	-259.0%

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	99.8%+79.8pp	20.0%0.0pp	20.0%0.0pp	20.0%0.0pp	20.0%0.0pp	20.0%0.0pp	20.0%-9.1pp	29.1%
Operating Margin	49.5%+16489.1pp	-16439.6%+4655.6pp	-21095.3%+31791.4pp	-52886.7%-14075.2pp	-38811.5%-38015.6pp	-795.9%+68.1pp	-864.1%+1581.8pp	-2445.8%
Net Margin	53.1%-2609.7pp	2662.7%+31846.0pp	-29183.2%+247.8pp	-29431.0%+13942.6pp	-43373.6%-42519.2pp	-854.4%+60.7pp	-915.1%+1554.0pp	-2469.1%
Return on Equity	60.3%+34.3pp	26.0%	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	12.7%+9.8pp	2.9%+20.8pp	-17.9%-11.2pp	-6.7%+1.7pp	-8.4%+2.8pp	-11.2%+3.5pp	-14.7%+42.3pp	-57.0%
Current Ratio	0.09-0.0	0.11+0.0	0.06-0.0	0.11+0.0	0.07-0.1	0.19+0.1	0.07-0.0	0.10
Debt-to-Equity	3.74+3.7	0.000.0	0.00+7.1	-7.06-6.2	-0.90+0.2	-1.09-0.4	-0.65+0.9	-1.57
FCF Margin	N/A	-12422.8%+8338.1pp	-20760.9%+29350.6pp	-50111.5%+19263.7pp	-69375.2%-68628.5pp	-746.8%-51.8pp	-695.0%+93.7pp	-788.7%

Note: The current ratio is below 1.0 (0.11), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Brainstorm Cell Therapeutics I BCLI

$12.0M

Aim Immunotech AIM

$6.4M

Pharmacyte Biotech Inc PMCB

$8.2M

Cyclerion Therapeutics Inc CYCN

$13.1M

Frequently Asked Questions

What is Hcw Biologics Inc.'s annual revenue?

Hcw Biologics Inc. (HCWB) reported $54K in total revenue for fiscal year 2025. This represents a -97.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Hcw Biologics Inc.'s revenue growing?

Hcw Biologics Inc. (HCWB) revenue declined by 97.9% year-over-year, from $2.6M to $54K in fiscal year 2025.

Is Hcw Biologics Inc. profitable?

No, Hcw Biologics Inc. (HCWB) reported a net income of -$8.0M in fiscal year 2025, with a net profit margin of -14677.1%.

What is Hcw Biologics Inc.'s EBITDA?

Hcw Biologics Inc. (HCWB) had EBITDA of -$12.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Hcw Biologics Inc. have?

As of fiscal year 2025, Hcw Biologics Inc. (HCWB) had $2.0M in cash and equivalents against $0 in long-term debt.

What is Hcw Biologics Inc.'s gross margin?

Hcw Biologics Inc. (HCWB) had a gross margin of 20.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Hcw Biologics Inc.'s operating margin?

Hcw Biologics Inc. (HCWB) had an operating margin of -24270.7% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Hcw Biologics Inc.'s net profit margin?

Hcw Biologics Inc. (HCWB) had a net profit margin of -14677.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Hcw Biologics Inc.'s return on equity (ROE)?

Hcw Biologics Inc. (HCWB) has a return on equity of -287.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Hcw Biologics Inc.'s free cash flow?

Hcw Biologics Inc. (HCWB) generated -$13.4M in free cash flow during fiscal year 2025. This represents a 7.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Hcw Biologics Inc.'s operating cash flow?

Hcw Biologics Inc. (HCWB) generated -$13.4M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Hcw Biologics Inc.'s total assets?

Hcw Biologics Inc. (HCWB) had $24.5M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Hcw Biologics Inc.'s capital expenditures?

Hcw Biologics Inc. (HCWB) invested $0 in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Hcw Biologics Inc. spend on research and development?

Hcw Biologics Inc. (HCWB) invested $5.4M in research and development during fiscal year 2025.

What is Hcw Biologics Inc.'s current ratio?

Hcw Biologics Inc. (HCWB) had a current ratio of 0.11 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Hcw Biologics Inc.'s debt-to-equity ratio?

Hcw Biologics Inc. (HCWB) had a debt-to-equity ratio of 0.00 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Hcw Biologics Inc.'s return on assets (ROA)?

Hcw Biologics Inc. (HCWB) had a return on assets of -32.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Hcw Biologics Inc.'s cash runway?

Based on fiscal year 2025 data, Hcw Biologics Inc. (HCWB) had $2.0M in cash against an annual operating cash burn of $13.4M. This gives an estimated cash runway of approximately 2 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Hcw Biologics Inc.'s Piotroski F-Score?

Hcw Biologics Inc. (HCWB) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Hcw Biologics Inc.'s earnings high quality?

Hcw Biologics Inc. (HCWB) has an earnings quality ratio of 1.68x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Hcw Biologics Inc. cover its interest payments?

Hcw Biologics Inc. (HCWB) has an interest coverage ratio of -15.6x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Hcw Biologics Inc.?

Hcw Biologics Inc. (HCWB) scores 17 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.